Omnicare — Q4 2014 Earnings Presentation
18 slides from Omnicare's earnings presentation, Feb 25, 2015
Slide 1: Fourth-Quarter & Full Year 2014 Financial Results Supplemental Slides
Fourth-Quarter & Full Year 2014 Financial Results Supplemental Slides
Slide 2: Forward-Looking Statements
Certain of the statements made today and listed within the following presentation slides are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, all statements regarding the intent, b
Slide 3: Table of Contents
3 Table of Contents Fourth-Quarter 2014 Highlights……………………………………………… Fourth-Quarter 2014 Segment Highlights………………………………….. Gross Profit & Adjusted Operating Income…………………………………. Adjusted Net Income & Cash EPS…………………………………………... Adjusted Operating Income by Segment……………………………………. Cash Flo
Slide 4: Continuing Operations Fourth-Quarter 2014 Highlights
Continuing Operations Fourth-Quarter 2014 Highlights Adjusted Cash-Based Earnings per Diluted Share(1) 4 Full Year 2014 Q4 2014 Discontinued Operations(2) Total $0.96 $0.00 $0.96 $3.72 $0.04 $3.77 Revenue of $1,628M 6.0% increase y/y 1. Each adjusted item excludes special items and discontinued oper
Slide 5: Fourth-Quarter 2014 Segment Highlights
Fourth-Quarter 2014 Segment Highlights(1) 5 Long-Term Care Group Specialty Care Group ■ 4Q14 Revenue of $1,185.0M up 1.4% from the prior year quarter - 4Q14 marked the fourth consecutive quarter of year-over-year revenue growth - Scripts from net new business added throughout 2014 up 52% in 4Q14 vs.
Slide 6: Gross Profit & Adjusted Operating Income
Prior Year In millions, except per share data and % 4Q 2014 3Q 2014 Increase / (Decrease) 4Q 2013 Increase / (Decrease) Net sales 1,627.9$ 1,608.1$ 1.2% 1,536.2$ 6.0% Cost of sales 1,273.5 1,256.6 1.3% 1,176.5 8.2% Gross profit 354.4$ 351.5$ 0.8% 359.7$ (1.5%) Rate 21.77% 21.86% (9 bps) 23.41% (164
Slide 7: Adjusted Net Income & Cash EPS
Adjusted Net Income & Cash EPS(1)(2) 7 1. Each amount is reported independently. The sum of the individual amounts may not equal the separately presented amounts due to rounding. 2. Each adjusted item excludes special items and discontinued operations. A reconciliation of non-GAAP information to the
Slide 8: Adjusted Operating Income by Segment
Adjusted Operating Income by Segment(1) 8 Full-year 2014 Long-Term Care adjusted operating income was consistent with prior year at $632.2M as efficiency benefits offset volume decreases Specialty Care Group 2014 adjusted operating income growth of 20.9% to $136.9M was driven by strong organic g
Slide 9: Cash Flows
Prior Year In millions, except % 4Q 2014 3Q 2014 Increase / (Decrease) 4Q 2013 Increase / (Decrease)(3) Net income / (Loss) (6.0)$ 64.8$ (109.3%) (83.7)$ 92.8% (Income) / Loss from discontinued operations (2.7)$ 3.2$ (184.4%) 142.3$ (101.9%) Adjustments to reconcile net income to net cash flows from
Slide 10: Cash Deployment
Cash Deployment 10 Repurchased 850 thousand shares for an aggregate amount of $60 million in 4Q14 Additional $15 million was paid up front for an Accelerated Share Repurchase (ASR) program; remaining shares delivered in 1Q15 Increased quarterly dividend 10% to $0.22 per share, marking the fift
Slide 11: Operating Metrics – Script Data
Prior Year In thousands, except % 4Q 2014 3Q 2014 Increase / (Decrease) 4Q 2013 Increase / (Decrease) Long-Term Care Group Scripts: Generic scripts dispensed 20,204 20,506 (1.5%) 20,404 (1.0%) Branded scripts dispensed 3,895 3,892 0.1% 4,215 (7.6%) Over-the-counter scripts dispensed 3,256 3,301 (1.4
Slide 12: Full-Year 2015 Guidance
Full-Year 2015 Guidance 1. Guidance provided on February 25, 2015. 2. Excludes special items and discontinued operations. A reconciliation of non-GAAP information to the comparable GAAP measures has been attached to our press release and is available on our website under ‘Supplemental Financial Info
Slide 13: Forward-Looking Major Financial Drivers
Forward-Looking Major Financial Drivers(1) 13 1. Information on this slide is not intended to represent the company’s financial guidance for 2015 and 2016. Volume growth – Long-Term Care 2014 Brand-to-generic Payer pricing 2015 2016 Key Drivers Volume growth – Specialty Care Brand drug price inflati
Slide 14: Appendix
RNY ly, “yg; Omnicare Appendix
Slide 15: Capital Structure
Capital Structure 4Q14 Initiatives Have Created More Predictable Debt Structure $252M $20M $20M $20M $315M $241M $400M $300M $80M $307M $424M $0M $200M $400M $600M 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2033 2042 2044 Previous Maturity Schedule Current Maturity Schedule Composition of Deb
Slide 16: Working Capital Management
Working Capital Management Five Quarter Trend(1) 40.1 32.9 29.5 36.2 37.5 41.7 43.3 39.2 37.3 32.7 25 30 35 40 45 50 55 60 65 70 75 5 10 15 20 25 30 35 40 45 4Q13 1Q14 2Q14 3Q14 4Q14 Days of Inventory On Hand (DOH) Days Sales Outstanding (DSO) 16 Efficiency initiatives have driven working capital im
Slide 17: Selected Branded Drug Patent Expirations
1. All generic launches are subject to change due to litigation or pediatric exclusivity. 17 2015 2016 Selected Branded Drug Patent Expirations(1) 1Q15 - Launched 2Q15 3Q15 4Q15 Androgel Clobex Spray Colcrys Focalin XR Lamictal ODT Stromectol (Tab) Zyvox IV Abilify Actonel Fazaclo ODT Oxytrol Renage
Slide 18: Fourth-Quarter & Full Year 2014 Financial Results Supplemental Slides
Fourth-Quarter & Full Year 2014 Financial Results Supplemental Slides